HUTCHMED (CHINA) LIMIT

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer

27 Jul 2021 20:00:00 By Nasdaq GlobeNewswire

Stabilizing Actions and End of Stabilization Period in connection with the Global Offering

23 Jul 2021 07:00:00 By Nasdaq GlobeNewswire

HUTCHMED’s Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

15 Jul 2021 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca

13 Jul 2021 02:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global Offering

12 Jul 2021 09:52:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China

05 Jul 2021 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2021 Half-Year Financial Results

02 Jul 2021 04:30:00 By Nasdaq GlobeNewswire

U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

01 Jul 2021 06:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces the Closing of the Global Offering and the Primary Listing in Hong Kong

30 Jun 2021 05:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Pricing of Global Offering

23 Jun 2021 10:22:40 By Nasdaq GlobeNewswire

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

22 Jun 2021 13:15:57 By Nasdaq GlobeNewswire

HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

18 Jun 2021 11:24:42 By Nasdaq GlobeNewswire

HUTCHMED Launches Hong Kong Initial Public Offering

17 Jun 2021 19:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program

20 May 2021 02:00:00 By Nasdaq GlobeNewswire

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

17 May 2021 02:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Attend Upcoming Investor Conferences

07 May 2021 07:00:00 By Nasdaq GlobeNewswire

Change of Company Name

04 May 2021 03:00:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

03 May 2021 07:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

08 Apr 2021 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

29 Mar 2021 02:00:00 By Nasdaq GlobeNewswire